A few biotech firms say they are getting close to being able to detect cancer early through blood tests, CNBC reports.

Current liquid biopsy tests monitor patients already diagnosed with cancer to see whether their disease is responding to treatment, it adds. But, according to CNBC, using the same approach, companies like Freenome, Grail, and Thrive are working to detect cancer in its early stages when it may be easier to treat.